French AI startup Bioptimus has raised $41 million to develop a foundational AI model aimed at understanding and simulating biological processes. This innovative model seeks to predict disease outcomes and enhance treatment strategies by leveraging sensitive clinical data. Co-founder Jean-Philippe Vert highlights its potential across various industries, akin to ChatGPT's capabilities in text generation. Founded just last year, Bioptimus has already accumulated $76 million in funding, showcasing the growing trend of AI investment in France's biotech sector. The latest round was led by Cathay Innovation, with significant participation from various venture firms.